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ABSTRACT 
Coronavirus disease 2019(COVID-19) is a global health emergency of serious health concern. 
However, there is no current medical treatment, although it is much needed for patient contracting the 
severe form of the disease. This systematic review was to explain the information regarding chloroquine 
for the treatment of COVID-19 via the data obtain from PubMed and other three trial Registries which 
were searched for review and the use of chloroquine in patients with COVID-19. Four articles were 
included (one narrative letter, one in-vitro study, one commentary and one editorial) and review on 
other 14 ongoing clinical trials in China. Chloroquine seems to have great potential in reducing the 
replication of SARS-CoV-2 (virus causing COVID-19) in vitro. There is high chance, pre-clinical 
evidence of effectiveness and information of safety from long-time clinical use for other indications to 
describe the clinical research on Chloroquine in patients with COVID-19. However, clinical description 
should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) 
framework or be ethically approved as a trial as stated by the World Health Organization. Safety data 
and data from high-quality clinical trials are urgently needed. 
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1 Introduction 
COVID-19 (Coronavirus Disease-2019) is a global health emergency that needs serious response. Patients 
having the acute type of the infection are approximately 15% of the cases (Wu and McGoogan, 2020). 
However, during this pandemic there is no special, effective and proven medical treatment. In vitro report 
has described that chloroquine, is an immunomodulant drug anciently used to cure malaria, is active in 
limiting viral multiplicity in other infections, including the SARS-associated coronavirus (CoV) and MERS-
CoV (Savarino et al., 2003).  
Chloroquine has been used globally for more than 70 years, and it is part of the World Health Organization 
(WHO) model list of essential medicines. It is also less expensive and has a necessary clinical safety profile 
(Colson et al., 2020). However, chloroquine does not treat pneumonia but it stops viral replication which in 
turn prevent further infection. Treatment of cloroquine is combined with antibiotics Azithromycin to treat 
the pneumonia infection (Golden and John, 2020). Some researcher suggested that pulmonary fibrosis and 
embolism is the primary cause of the pneumonia associated with Covid-19. That this is one of the major 
reasons, ventilating the lungs does not improve the lungs function. 
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A systematic review was obtained from PubMed databases from inception to 1-March- April 2020 to search 
for articles that are providing information using the following keyword to search on the potency, efficacy 
and safety of chloroquine and chloroquine related formulations in patients with SARS-CoV-2 pneumonia 
and articles describing related in-vitro studies.  
The information obtained on COVID-19 are coming from Asia, no language restrictions were imposed. 
The search was expanded using a snowballing method applied to the references of retrieved papers.  The 
search paper also focuses on the Chinese Clinical Trial Registry, Clinical trial. gov and the International 
Clinical Trials Registry Platform (WHO ICTRP) to identify ongoing trials.  
Table 1: Characteristics of clinical trials studying the efficacy and safety of Chloroquine or related formulation 
in patients with new coronavirus pneumonia (COVID-19) (Gao et al., 2020). 
ID Recruitin
g Status  
Number of 
centers and 
Study 
design 
Countr
y 
Populatio
n (n 
patients)  
Intervention 
Group(s) 
Comparison 
Group(s)  
Primary 
Outcomes 
ChiCTR20000304
17  
Not yet 
recruiting 
Single 
Center RCT 
China COVID-
19 
pneumoni
a (n = 30)  
Chloroquine 
phosphate 
aerosolized 
inhalation solution 
Water for 
injection 
atomized 
inhalation 
combined  
Temperatur
e normal for 
more than 3 
days, 
respiratory 
symptoms, 
pulmonary 
imaging, 
test (Gao et 
al., 2020). 
ChiCTR20000300
54  
Pending 
approval 
Single 
Center RCT  
China Mild and 
common 
COVID-
19 
pneumoni
a (n = 
100) 
Hydroxychloroquin
e sulfate group: 
Hydroxychloroquin
e sulfate and 
Chloroquine 
phosphate group: 
First dose of 
chloroquine 
phosphate 
Standard 
treatment  
Clinical 
recovery 
time (Wang 
et al., 2020). 
ChiCTR20000300
31  
Recruitin
g 
Single 
Center RCT  
China Mild and 
common 
COVID-
19 
pneumoni
a (n = 
120) 
2 tablets 
Chloroquine 
phosphate BID 
2 tablets 
placebo BID 
Time of 
conversion 
to be 
negative of 
novel 
coronavirus 
nucleic acid 
(Yang et al., 
2020) 
ChiCTR20000299
92  
Pending 
approval 
Single 
Center RCT  
China Severe 
COVID-
19 
pneumoni
a (n = 
100) 
Chloroquine 
phosphate group: 
Chloroquine 
phosphate 1.0 g × 
2 days, then 0.5 g × 
12 day from the 
third day 
Hydroxychloroquin
e sulfate group: 
Standard 
treatment  
Clinical 
recovery 
time; 
Changes in 
viral load of 
upper and 
lower 
respiratory 
tract 
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Hydroxychloroquin
e sulfate 0.2 g BID 
x 14 days 
samples 
compared 
with the 
baseline 
(Huang et 
al., 2020). 
ChiCTR20000299
88  
Recruitin
g 
Single 
Center RCT 
China Severe 
COVID-
19 
pneumoni
a (n = 80)  
Chloroquine 
phosphate 
Standard 
treatment  
Time to 
Clinical 
Recovery 
(Gao et al., 
2020) 
ChiCTR20000299
75 Chin 
Pending 
approval 
Single 
Center 
Single-arm 
clinical trial 
China COVID-
19 
pneumoni
a (n = 10) 
150 mg 
chloroquine 
phosphate 
dissolved in 5 ml of 
normal saline, 
q12h, inhaled by 
atomization for one 
week 
No 
comparison 
group 
Viral 
negative-
transformin
g time; 30-
day cause-
specific 
mortality; 
Co-
infections; 
Time from 
severe and 
critical 
patients to 
clinical 
improveme
nt (Lenk 
and Duttge, 
2020) 
ChiCTR20000299
39  
Recruitin
g  
Single 
Center RCT  
China COVID-
19 
pneumoni
a (n = 
100)  
Chloroquine 
phosphate 
Standard 
treatment 
Length of 
hospital stay 
(Geo et al., 
2020) 
ChiCTR20000299
35  
Recruitin
g 
Single 
CenterSingl
e-arm 
clinical trial 
China COVID-
19 
pneumoni
a (n = 
100)  
Chloroquine 
phosphate 
No 
comparison 
group 
Length of 
hospital stay 
(Gao et al., 
2020) 
ChiCTR20000298
03  
Pending 
approval 
Single 
Center RCT 
China Close 
contacts 
with 
suspected 
or 
confirmed 
cases, and 
positive 
test of 
COVID-
19 nucleic 
acid (n = 
320) 
Group A1: 
Hydroxychloroquin
e, small dose; 
Group A2: 
Hydroxychloroquin
e, high dose 
Group B1: 
Abidol 
hydrochlorid
e low dose; 
Group B2: 
Abidol 
hydrochlorid
e high dose 
Progression 
to suspected 
or 
confirmed 
disease 
within 24 
days (Wang 
et al., 2020) 
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ChiCTR20000297
61  
Recruitin
g  
Multi-
Center RCT  
China Common 
COVID-
19  
Low-dose group: 
Low-dose 
hydroxychloroquin
e; 
Standard 
treatment  
Negative 
conversion 
rate of 
COVID-19 
nucleic acid; 
lung 
ChiCTR20000297
40  
Recruitin
g  
Single 
Center RCT 
China COVID-
19 
pneumoni
a (n = 78) 
Oral intake 
hydroxycholoroqui
ne 0.2 g BID 
Standard 
Treatment 
Negative 
conversion 
rate of 
COVID-19 
nucleic acid; 
prognosis; 
oxygen 
index; 
respiratory 
rate; lung 
radiography; 
temperature
; count of 
lymphocyte; 
temperature
; other 
infections 
(Huang et 
al., 2020) 
ChiCTR20000295
42  
Recruitin
g  
Single 
center 
prospective 
cohort 
study 
China COVID-
19 
pneumoni
a (n = 20) 
Oral chloroquine 
0.5 g BID for 10 
days 
Standard 
treatment 
Negative 
conversion 
rate of 
COVID-19 
nucleic acid; 
30-day 
cause 
specific 
mortality 
(Gao et al., 
2020) 
NCTO4261517 Not yet 
recruiting  
Single 
center RCT  
China COVID-
19 
pneumoni
a (n = 30)  
Hydroxychloroquin
e 400 mg/day for 5 
days 
Standard 
treatment  
Mortality 
rate at day 
14; 
Virological 
clearance 
rate of 
throat 
swabs, 
sputum, or 
lower 
respiratory 
tract 
secretions at 
day 3,5,7 
(Guan et al., 
2020) 
 
The number of patients in the Population columns refers to the reported sample size. 
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2 Discussion 
The initial search identified 50 sources (30 were from PubMed, 25 was found in EMBASE and 5 from 
other sources). Following screening of titles and abstracts and removing duplicates, evaluation was made 
on eight articles in full text, among these, four relevant articles (one narrative letter, one research letter, one 
editorial and one commentary) (Gao et al., 2020; Wang et al., 2020). Fourteen trials were found in the trial 
registries (Table 1). 
The research letter, written by a group of Chinese researchers, studied the effect of chloroquine in vitro, 
using Vero E6 cells infected by SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05. The study 
demonstrated that Chloroquine was highly effective in reducing viral replication, with an Effective 
Concentration (EC) 90 of 6.90 μM that can be easily achievable with standard dosing, due to its favorable 
penetration in tissues, including in the lung (Wang et al., 2020). The authors explained that chloroquine is 
known to block virus infection by increasing endosomal pH and by interfering with the glycosylation of 
cellular receptor of SARSCoV. The authors also speculated on the possibility that the known 
immunomodulant effect of the drug may enhance the antiviral effect in vivo (Zhonghua et al., 2020). 
Since cases were reported in 85 countries so far (5th March 2020), the low cost of chloroquine is a major 
benefit for both the highly stressed healthcare systems of involved high-income countries and the 
underfunded healthcare systems of middle- and low-income counties (Farner, 2020). The expert consensus 
was published on 20th February by a multicentre collaboration group of the Department of Science and 
Technology of Guangdong Province and Health Commission of Guangdong Province paper and related 
specifically to the use of Chloroquine phosphate (Zhonghua et al., 2020). No information was provided on 
the method used to achieve consensus. 
Based on in vitro evidence and still unpublished clinical experience, the panel recommended chloroquine 
phosphate tablet, at a dose of 500 mg twice per day for 10 days, for patients diagnosed as mild, moderate 
and severe cases of SARS-CoV-2 pneumonia, provided that there were no contraindications to the drug. 
The panel recommended using several precautions, including blood testing to rule out the development of 
anemia, thrombocytopenia or leukopenia as well as serum electrolyte disturbances and/or hepatic and renal 
function dysfunction.  
Also recommended were routine electrocardiographies to rule out the development of QT interval 
prolongation or bradycardia and patient interviews to seek the appearance of visual and/or mental 
disturbance/deterioration. The panel recommended avoiding concurrent administration of other drugs 
known to prolong the QT interval (i.e. chinolones, macrolides, ondansetron) as well as various 
antiarrhythmic, antidepressant and antipsychotic drugs (Gao et al., 2020). 
The Dutch Center of Disease control (CDC), in a public document on its website, suggested to treat severe 
infections requiring admission to the hospital and oxygen therapy or admitted to the ICU with Chloroquine 
(James et al., 2020). However, the study also stated that treating patients only with optimal supportive care 
is still a reasonable option, due to lack of supportive evidence. The suggested regimen in adults consists of 
600 mg of chloroquine base (6 tablets A-CQ 100 mg) followed by 300 mg after 12 h on day 1, then 300 mg 
× 2/daily per os on days 2–5 days. This study also underlined the needs for stopping the treatment at day 
5 to reduce the risk of side effects, considering the long half-life of the drug (30 h); 2) the need to 
differentiate between regimens based on Chloroquine phosphate and Chloroquine base since 500 mg of 
the first correspond to 300 mg of the second (Yang et al., 2020). 
Another guideline document by the Italian Society of Infectious and Tropical disease (Lombardy section) 
recommend the use of chlorochine 500 mg × 2/daily or hydroxychloroquine 200 mg die for 10 days, 
although the treatment may vary from 5 to 20 days according to clinical severity. The suggested target 
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population ranged from patients with mild respiratory symptoms and comorbidities to patients with severe 
respiratory failure (Haung et al., 2020).  
Search also identified ongoing 14 trials, all in China (Table 1). The trials varied in study design, severity of 
the disease in the target population and in dosing and duration of the treatment. Indeed, the trial 
registrations varied also in quality of the reported information. That so many such studies are being 
conducted in parallel suggests that that the scientific community is making a huge effort to clarify this 
question, but this effort is probably insufficiently coordinated. In support of this observation, the Chinese 
authorities have recently issued a directive to regulate and coordinate clinical trials studying potential 
pharmacological treatments for COVID-19. The results of these trials will be the first available on humans, 
since studies published to date on the characteristics and management of patients with COVID-19 did not 
report data about Chloroquine use (Wang et al., 2020). 
Of note, the WHO published a generic protocol for randomized clinical trials to investigate the clinical 
efficacy and safety of drugs in hospitalized patients with COVID19 (i.e. a “master template” for researching 
drugs in this setting) (Farner, 2020). The vital ethical issue is whether administration of chloroquine in the 
setting of COVID-19 is experimental, and therefore requires ethical trial approval, or off-label (i.e. ethically 
justifiable as the best available treatment). Additional information on chloroquine will soon be released in 
the context of the evolving outbreak (Guan et al., 2020). 
Timely release of this information can be of importance due to the growing number of infected patients, 
and the absence of licensed specific drugs. Meanwhile, the recommendations for “Clinical management of 
severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected”, published 
by the WHO, confirm that there is currently no evidence from RCTs to inform on specific drug treatment 
of COVID-19 and that unlicensed treatments should be administered only in the context of ethically-
approved clinical trials or the Monitored Emergency Use of Unregistered Interventions Framework 
(MEURI), under strict monitoring (Wu and McGoogan, 2020). 
The WHO therefore seems to view Chloroquine as experimental. The authors tend to agree with this 
viewpoint. But even off-label use of Chloroquine may be accompanied by several concerns; the first is 
patient safety. Such use should be accompanied by close monitoring. An epidemic is hardly the ideal setting 
to do this. The ethical approach to off-label drug use also differs between countries, raising questions 
regarding equity. Finally, chloroquine remains a pivotal drug in the treatment of malaria in many places in 
the world. Off label drug use can create major drug shortages. 
3 Conclusion  
There is sufficient pre-clinical information, data and evidence regarding the potency and activeness of 
chloroquine for treatment of COVID-19 as well as evidence of safety from long-time use in clinical practice 
for other indications to describe clinical research on the topic. The current situation explained the 
prioritization of the systematic review of study proposals above other. Although the use of chloroquine 
may be supported by expert opinion, clinical use of this drug in patients with COVID-19 should adhere to 
the MEURI framework or after ethical approval as a trial as stated by the WHO. Data from high-quality, 
coordinated, clinical trials coming from different locations worldwide are greatly required. 
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